Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETVAX for Prevention of ETEC Diarrhea in Travelers to West Africa
NCT03729219Phase 2Completed
- Sponsor
- Scandinavian Biopharma
- Start
- Jun 2017
- Primary completion
- Apr 2019
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traveler's diarrhea (TD) and enterotoxigenic Escherichia coli infection comparing ETVAX with Placebo (2 arms). Primary endpoints: Number of vaccine attributable adverse events, Fold change of serum titers of IgA and IgG against LTB and 4 more. Started Jun 2017; status: completed.
02
Drugs
oral tetravalent ETEC vaccine
03
Conditions
traveler's diarrhea (TD)enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT03729219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729219.